Evidence map›Paper›PMID 42130478›Full record

ArticleNucleic acids research2026

SynCraft: an integrated web server for ADMET-aware retrosynthesis and molecular design.

Qahtan Adnan Aljanabi, Zhijian Huang, Jinmiao Song, Lei Deng

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Qahtan Adnan AljanabiSchool of Computer Science and Engineering, Central South University, Changsha 410083, China.
Zhijian HuangSchool of Computer Science and Engineering, Central South University, Changsha 410083, China.ORCID 0009-0000-1949-167X
Jinmiao SongSchool of Software, Xinjiang University, Urumqi 830046, China.ORCID 0000-0003-0847-9813
Lei DengSchool of Computer Science and Engineering, Central South University, Changsha 410083, China.ORCID 0009-0005-7749-1930

Funding

National Natural Science Foundation of China 62272490Natural Science Foundation of Hunan Province 2025JJ20062
6 · The paper itself

Abstract

The efficient design of drug candidates requires simultaneous consideration of synthetic feasibility and pharmacokinetic safety. However, current computational tools typically address retrosynthetic planning and ADMET evaluation as separate tasks, requiring users to manually transfer data between platforms and evaluate candidate molecules in a sequential and time-consuming manner. Here, we present SynCraft, a web server that integrates template-based retrosynthesis with real-time ADMET evaluation within a unified workflow. SynCraft accepts molecular input via SMILES, interactive drawing, or file upload, and performs automated multi-step retrosynthetic planning while simultaneously assessing the safety and drug-likeness of all intermediate compounds. ADMET properties are predicted using a multi-view learning framework, and potentially hazardous intermediates are automatically highlighted with intuitive, colour-coded warnings during route exploration. The server further provides integrated analysis tools, including synthetic accessibility and complexity scoring, drug-likeness evaluation, and interactive 2D/3D visualization, enabling users to seamlessly transition from route generation to detailed molecular assessment. Results are presented through an interactive interface that allows comparison of alternative synthetic routes, with downloadable outputs in standard formats. In a case study of imatinib, SynCraft automatically identifies genotoxic intermediates that are typically overlooked in conventional retrosynthesis workflows, demonstrating its practical utility for safety-aware route design. The web server is freely accessible at https://syncraft.denglab.org.

Indexed as

Drug DesignSoftwareImatinib MesylateInternetUser-Computer InterfaceImatinib Mesylate

Identifiers

PMID42130478
PMCPMC13355069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.